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Postoperative deep infection after bone tumor surgery remains a serious complication.
Although there are numerous reports about risk factors for postoperative deep infection in
general surgery, there is only a small number of reports about those for bone tumor surgery.
This retrospective study aimed to identify risk factors for postoperative deep infection after
bone tumor resection.
Methods
We reviewed data of 681 patients (844 bone tumors) who underwent surgery. Associations
between variables, including age, recurrent tumor, pathological fracture, surgical site (pel-
vis/other), chemotherapy, biological reconstruction, augmentation of artificial bone or bone
cement, the use of an implant, intraoperative blood loss, operative time, additional surgery
for complications, and postoperative deep infection were evaluated.
Results
The rate of postoperative deep infection was 3.2% (27/844 tumors). A pelvic tumor (odds
ratio [OR]: 3.4, 95% confidence interval [CI]: 1.0–11.3) and use of an implant (OR: 9.3, 95%
CI: 1.9–45.5) were associated with an increased risk of deep infection.
Conclusions
This retrospective study showed that pelvic tumor and use of an implant were independent
risk factors for deep infection. This information will help surgeons prepare an adequate sur-
gical plan for patients with bone tumors.
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Introduction
Deep infection is one of the most serious complications after surgery. Postoperative deep
infection usually requires additional surgery, the prolonged use of antibiotics, and delays in
scheduled treatment such as chemotherapy. Among orthopaedic surgeries, 9–36% of patients
had deep infection after bone tumor surgery [1–5]. McDonald et al. reported that 11.8% of
patients who received limb salvage surgery experienced infection, and 22.2% of patients with
postoperative infection underwent amputation [6]. To improve the outcome of bone tumor
surgery, the risk of each surgery should be assessed and patients with high risk of deep infec-
tion should be treated with preventive measures such as nutritional optimization, periopera-
tive antibiotics or MRSA nasal screening and decolonization. Although there are numerous
reports describing risk factors for postoperative deep infection after orthopedic surgery,
including arthroplasty and spine surgery, only a small number of studies have reported those
after bone tumor surgery [5,7–11]. In the reports, African-American race, local infection at the
limb sparing surgery, lower WBC, BMI, age, total number of procedures, preexisting implants,
infection at another site, malignant disease, hip region affected, and duration of the procedure,
were independent risk factor for deep infection after bone tumor surgery [5,7,9,11]. To choose
adequate surgical treatment, it is important to assess the risk of postoperative deep infection in
each patient preoperatively. In the present study, the frequency of postoperative deep infection
and correlations of deep infection with various clinical parameters, including age, the tumor
location, the use of an implant, chemotherapy, the use of artificial bone or cement, operative
time, intraoperative blood loss, biological reconstruction, and additional surgery for complica-
tions, were investigated to identify risk factors for postoperative deep infection.
Methods
Patients
This was a single-center, retrospective case study. Overall, 681 patients with 844 bone tumors,
who underwent surgery between January 1995 and December 2015, were enrolled in this
study. Metastatic bone tumors were excluded from this study. The study patients comprised
390 men and 291 women whose ages ranged from 1 to 92 years (mean age, 28.0 years). The
tumor diagnoses were confirmed through histopathological examinations (Table 1). Bone
tumors located in the femur (n = 273), tibia (n = 176), humerus (n = 95), pelvis (n = 80), foot
(n = 64), hand (n = 58), fibula (n = 33), rib (n = 17), scapula (n = 14), ulna (n = 14), radius
(n = 14), clavicle (n = 4), sternum (n = 1), and patella (n = 1) were included in this study
(Table 2). Patients with spine tumors and those who underwent surgery using implants with
an antimicrobial coating were excluded from this study. The reconstructions after resection
of bone tumors were classified into: no reconstruction, biological reconstruction, implant
replacement, use of artificial bone or cement, or composite use of the materials. This retrospec-
tive study was approved by the ethics committee of Kanazawa University. All data were fully
anonymized before access by the researchers, and the ethics committee waived the require-
ment for informed consent.
Outcome measure
In this study, the incidence of postoperative deep infection and its association with various fac-
tors were evaluated. The optimal cutoff levels for age, the operative time, and intraoperative
blood loss were identified in receiver operator characteristic curve analysis. The patient-related
parameters were as follows: age (<20 or20 years), location of the tumor (pelvis or other),
recurrent tumor (yes/no), pathological fracture (yes/no), and chemotherapy (yes/no). The
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surgery-related parameters were as follows: the use of an implant (yes/no), biological recon-
struction (yes/no), use of artificial bone or bone cement for bone defect (yes/no), additional
surgery for complications (yes/no), operative time (<5 or5 hours), and intraoperative blood
loss (<150 or150 mL). Biological reconstruction was defined as the use of allograft, iliac
bone, fibular bone, tibial bone, and tumor-bearing bone treated by freezing or autoclaving, for
bone defect after bone tumor resection [12]. Artificial bone was defined as α-tricalcium
Table 1. Diagnoses of the lesions.
Benign tumor Malignant tumor
Diagnosis Number of lesions Diagnosis Number of lesions
Osteochondroma 195 Osteosarcoma 102
Bone cyst 126 Chondrosarcoma 55
GCT 83 MFH/UPS 20
Enchondroma 70 Ewing sarcoma 13
Fibrous dysplasia 27 Hemangiopericytoma 2
Chondroblastoma 20 Adamantinoma 2
NOF 20 Fibrosarcoma 1











MFH, malignant fibrous histiocytoma; UPS, undifferentiated pleomorphic sarcoma; GCT, giant cell tumor; NOF, non-ossifying fibroma; ABC, aneurysmal
bone cyst; OFD, osteofibrous dysplasia; LCH, Langerhans cell histiocytosis; BPOP, bizarre parosteal osteochondromatous proliferation
https://doi.org/10.1371/journal.pone.0187438.t001
Table 2. Locations and incidence of postoperative deep infection.
Locations Number of tumors Infection (%)
Femur 273 5 (1.8%)
Tibia 176 13 (7.4%)
Humerus 95 1 (1.1%)
Pelvis 80 7 (8.8%)
Foot 64 1 (1.6%)
Hand 58 0 (0%)
Fibula 33 0 (0%)
Rib 17 0 (0%)
Scapula 14 0 (0%)
Ulna 14 0 (0%)
Radius 14 0 (0%)
Clavicle 4 0 (0%)
Sternum 1 0 (0%)
Patella 1 0 (0%)
Total 844 27 (3.2%)
https://doi.org/10.1371/journal.pone.0187438.t002
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phosphate (TCP) or β-TCP. Bone cement was defined as polymethylmethacrylate. Additional
surgeries for complications were defined as surgical treatment for delayed bone union, frac-
ture, wound dehiscence, breakage of implants, hematoma, and intestinal perforation. Postop-
erative deep infections were defined using the US Centers for Disease Control classifications
for surgical site infections [13].
Statistical analysis
To identify the risk factors for postoperative deep infection after bone tumor surgeries, univar-
iate analysis was performed using the Fisher exact test. Multiple logistic regression analysis
was used to identify the independent risk factors for postoperative deep infection. The parame-
ters with univariate p values <0.1 were considered as candidates for the multiple logistic
regression model. Statistical significance was defined as p< 0.05, and all analyses were per-
formed using statistical software (EZR, Saitama Medical Center, Jichi Medical University).
Results
Risk factors for postoperative deep infection
Among the study patients, the incidence of postoperative deep infection was 3.2% (27/844
operations). Results of univariate analyses showed that a pelvic tumor, chemotherapy, the use
of an implant, biological reconstruction, additional surgery for complications, operative time
5 hours, and intraoperative blood loss150 mL were significantly associated with an
increased risk of postoperative deep infection (Tables 3 and 4). The use of artificial bone or
cement was significantly associated with a decreased risk of postoperative deep infection.
Multiple logistic regression analysis included the following 8 variables: pelvic tumor, chemo-
therapy, the use of an implant, biological reconstruction, augmentation of artificial bone or
cement, additional surgery for complications, operative time5 hours, and intraoperative
blood loss150 mL. Result of multivariate analysis showed that pelvic tumor and use of an
implant were significantly associated with an increased risk of postoperative infection (Table 5).
Discussion
The treatment of bone tumors includes surgery, chemotherapy, radiation therapy, medica-
tions, and immunotherapy [14,15]. Surgical treatment for bone tumors comprises tumor
Table 3. Results of univariate analysis of the patient-related parameters.
Factor Number (%) of tumors with deep infection OR 95% CI p value
Age 20 years 18/429 (4.2%) 2.23 0.91–5.99 0.072
<20 years 8/415 (1.9%)
Tumor location Pelvis 7/80 (8.8%) 3.75 1.29–9.71 0.008
Other 19/764 (2.5%)
Recurrent tumor Yes 2/95 (2.1%) 0.65 0.07–2.69 0.758
No 24/749 (3.2%)
Pathological fracture Yes 0/37 (0%) 0.00 0.00–3.38 0.623
No 26/807 (3.2%)
Chemotherapy Yes 16/108 (14.8%) 12.55 5.18–31.94 < 0.001
No 10/736 (1.4%)
OR, odds ratio; CI, confidence interval.
The p values were calculated with Fisher exact test.
https://doi.org/10.1371/journal.pone.0187438.t003
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resection and reconstruction for bone defects using an endoprosthesis, allograft, autograft, and
artificial bone graft. The surgical outcomes of bone tumors such as limb function, recurrence,
and complications can be influenced by several factors, including age, tumor histology (pri-
mary or metastatic tumor), chemotherapy, radiation therapy, and the surgical site. Among the
complications, postoperative deep infection remains a common and severe complication after
bone tumor surgery. The causes of the postoperative deep infection after tumor resection
include immunocompromised patients with cancer, malnutrition, large bone and soft tissue
defects, a long operative time, frequent red blood cell and platelet transfusions, neutropenia
from postoperative chemotherapy, and frequent bacteremia from the use of indwelling central
venous catheters [16]. The rate of postoperative deep infection after resection of bone tumor
has been reported to range from 0.9% to 36% [3,4,17–20]. Postoperative deep infection
requires additional treatment such as irrigation surgery, the use of antibiotics for a long period,
and delays in the treatment course, which increases mortality. To improve the outcomes of
patients with bone tumors, physicians need to recognize the risk factors for postoperative deep
infection to determine the adequate surgical procedure.
Dietz et al. reported that 58% of orthopedic surgeries had bacterial contamination [21].
According to an intraoperative experiment, surgical wound, local bone harvested from surgical
Table 4. Results of univariate analysis of the surgery-related parameters.
Factor Number (%) of tumors with deep infection OR 95% CI p value
Use of an implant Yes 22/130 (16.9%) 35.89 11.88–145.94 < 0.001
No 4/714 (0.6%)
Biological reconstruction Yes 21/134 (15.7%) 26.02 9.31–90.21 < 0.001
No 5/710 (0.7%)
Artificial bone or cement Yes 2/305 (0.7%) 0.14 0.02–0.58 0.001
No 24/539 (4.5%)
Additional surgery for complications Yes 8/36 (22.2%) 12.43 4.30–33.32 < 0.001
No 18/808 (2.2%)
Operative time 5 h 18/84 (21.4%) 25.39 10.06–70.29 < 0.001
<5 h 8/760 (1.1%)
Intraoperative blood loss 150 mL 21/259 (8.1%) 10.20 3.69–35.06 < 0.001
<150 mL 5/585 (0.9%)
OR, odds ratio; CI, confidence interval.
The p values were calculated with Fisher exact test.
https://doi.org/10.1371/journal.pone.0187438.t004
Table 5. Risk factors for postoperative deep infection according to multivariate analysis.
Factor OR 95% CI p value
Pelvic tumor 3.42 1.04–11.30 0.044
Operative time5 h 2.17 0.63–7.49 0.221
Use of an implant 9.28 1.89–45.50 0.006
Biological reconstruction 4.20 0.96–18.30 0.057
Chemotherapy 2.18 0.74–6.42 0.156
Additional surgery for complications 1.57 0.53–4.63 0.412
Artificial bone or cement 1.65 0.25–10.80 0.603
Intraoperative blood loss 150 mL 0.76 0.20–2.96 0.693
OR, odds ratio; CI, confidence interval.
Values were calculated by multiple logistic regression analysis.
https://doi.org/10.1371/journal.pone.0187438.t005
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sites, surgeon’s gloves, and implants were contaminated by the same bacteria that were cul-
tured from the room air of the operating room, and the degree of contamination increased
proportionally with the exposure time [22]. The National Nosocomial Infections Surveillance
(NNIS) has identified an operative time of4 hours as being predictive of deep infection after
general surgery procedures [23].
The associations between postoperative deep infection and chemotherapy, and radiation
therapy are controversial. Leukocytopenia and neutropenia due to chemotherapy and tissue
damage caused by radiation therapy are thought to be associated with postoperative deep
infection. However, a study about the risk factors of postoperative infection showed that adju-
vant chemotherapy and radiotherapy were not significant risk factors for infection [11]. On
the other hand, a study on spinal metastases showed that radiation therapy was an indepen-
dent risk factor for postoperative infection [24].
Our present study revealed that pelvic tumors significantly increased the risk of postopera-
tive deep infection. Deep infection is one of the most frequent postoperative complications
after pelvic surgery (range, 20–36%), and it requires surgical debridement and irrigation
[1,3,17,20,25]. Bone tumors of the pelvis are often large, because they are diagnosed late. Fur-
thermore, choosing an adequate surgical treatment is particularly difficult because of the size
of the tumor, and its relationship to neurovascular structures and the urinary and intestinal
tracts. Among the surgeries for bone tumors, pelvic reconstruction after the resection of bone
sarcomas is challenging. Angelini et al. reported that pelvic reconstruction was an independent
significant risk factor for infection, and 46% of patients with infection required removal of the
reconstruction [1].
Our present study’s results showed that use of implant was associated with an increased risk
of postoperative deep infection. In general surgery, biomaterial has been considered to be a risk
factor of postoperative deep infection [26]. Previous studies have reported that 9–28% of cases
of deep infection occur after endoprosthetic reconstruction [2,4,16,17]. In contrast, reconstruc-
tion without an implant is associated with a low infection rate (0.9–1.2%) [19,27,28]. However,
infection following biological reconstruction using allograft or autograft is common. Mankin
reported that 13% of patients treated with allograft experienced infection [29]. Tsuchiya et al.
reported that 11% of patients, who underwent reconstruction using autograft containing tumor
treated by liquid nitrogen, had postoperative deep infection [30]. Our study’s findings showed
marginal significance for a correlation between biological reconstruction and postoperative
deep infection. Thus, the presence of biological reconstruction may influence the incidence of
infection.
To decrease postoperative deep infection, preventive care, including drainage and the
administration of prophylactic antibiotics, is needed after bone tumor surgeries. Recently, sev-
eral new techniques, including antibiotic-impregnated cement and an implant with silver coat-
ing or iodine coating, have been used to prevent deep infection after orthopaedic surgery [31–
34]. More efforts should be made to decrease postoperative deep infection in patients with a
high risk of infection.
In conclusion, our present study’s findings showed that a pelvic tumor and the use of an
implant are associated with an increased risk of postoperative deep infection. Surgeons will be
able to use this information when deciding which operative procedure to use to treat patients
with bone tumors.
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